Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Gene Therapy
Researchers from Boston University detail findings in cancer gene therapy
April 28th, 2009
A new study, 'Potentiation of methoxymorpholinyl doxorubicin antitumor activity by P450 3A4 gene transfer,' is now available. According to a study from the United States, "Preclinical and clinical studies of CYP gene-directed enzyme prodrug therapy have been focused on anticancer prodrugs activated by CYP2B enzymes, which have low endogenous expression in human liver; however, the gene therapeutic potential of CYP3A enzymes, which are highly expressed in human liver, remains unknown. This study investigated methoxymorpholinyl doxorubicin (MMDX; nemorubicin), a novel CYP3A-activated anticancer prodrug." "Retroviral transfer of CYP3A4 increased 9L gliosarcoma cell...
Source: Cancer Weekly (2009-04-28)
|
